Health · Policy
Trump Signs Order to Speed Psychedelic Research, Including Ibogaine
The FDA will fast-track reviews of three psychedelics and clear the way for the first U.S. human trials of ibogaine. Researchers say the drug carries serious heart risks and the evidence is thin.